{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single-agent+chemotherapy&page=2", "query": { "intervention": "Single-agent chemotherapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single-agent+chemotherapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T20:07:30.556Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03542110", "title": "The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Saphenous Vein Graft Atherosclerosis" ], "interventions": [ { "name": "Alirocumab 150 MG/ML subcutaneous injection", "type": "DRUG" }, { "name": "Matching Placebo subcutaneous injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Minneapolis Heart Institute Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2018-08-04", "completion_date": "2020-07-31", "has_results": false, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 4, "location_summary": "San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03542110" }, { "nct_id": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-11-06", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 38, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302025" }, { "nct_id": "NCT06864988", "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Neovascularization Secondary to Age-Related Macular Degeneration" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-03-03", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 91, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06864988" }, { "nct_id": "NCT00907413", "title": "Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cholangiocarcinoma" ], "interventions": [ { "name": "ERCP and Photodynamic Therapy", "type": "PROCEDURE" }, { "name": "ERCP only", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-05", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 1, "location_summary": "Charlotteville, Virginia", "locations": [ { "city": "Charlotteville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00907413" }, { "nct_id": "NCT01477879", "title": "Hsv 1 and 2 Gowey Protocol Versus Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Herpes" ], "interventions": [ { "name": "Versabase gel with sarracenia purpurea 20% liquid extract", "type": "OTHER" }, { "name": "placebo (versabase gel only)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Naturopaths International", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-01", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2011-11-23", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 1, "location_summary": "Flagstaff, Arizona", "locations": [ { "city": "Flagstaff", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01477879" }, { "nct_id": "NCT03849690", "title": "A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-906", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2019-02-27", "completion_date": "2019-04-15", "has_results": true, "last_update_posted_date": "2021-06-15", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849690" }, { "nct_id": "NCT04554732", "title": "Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Alopecia", "Chemotherapy-Induced Change", "Hair Loss", "Alopecia Drugs" ], "interventions": [ { "name": "Keratinocyte growth factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2020-04-27", "completion_date": "2022-06-24", "has_results": false, "last_update_posted_date": "2022-12-16", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04554732" }, { "nct_id": "NCT07183709", "title": "Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "PepGNP-COVID19", "type": "BIOLOGICAL" }, { "name": "Sterile Water for Injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 60, "start_date": "2026-02-02", "completion_date": "2026-10-18", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07183709" }, { "nct_id": "NCT06172127", "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection", "type": "DRUG" }, { "name": "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedSIR", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2024-07-22", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172127" }, { "nct_id": "NCT01557842", "title": "Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ventricular Tachycardia", "Ischemic" ], "interventions": [ { "name": "Drug Treatment", "type": "DRUG" }, { "name": "Catheter Ablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Biosense Webster, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2012-06-01", "completion_date": "2014-03-19", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-09-27T20:07:30.556Z", "location_count": 23, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01557842" } ] }